To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.
Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes in the UK.
Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to
At Prime Minister’s Questions on 19 October, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson
Numinus has completed C$40.3 million in bought deal financing and recently reported quarterly revenues over C$500,000. In September the company
Small Pharma recently completed a Phase I trial to treat Major Depressive Disorder (MDD), with proprietary DMT formulation SPL026. The
On Monday, 4 October, PSYCH released the third edition of The Psychedelics as Medicine Report. The 200+ page report examines
In the research briefing: How ayahuasca ceremony leaders regard preparation and integration Psychedelics for treating neurodegenerative disorders such as Alzheimer’s
Professor David Nutt is the Chief Research Officer at Awakn Life Sciences. A former Director of the Neuropsychopharmacology Unit at Imperial
Robert Tessarolo has 25 years’ experience in the pharmaceutical industry, holding Chief Executive roles over two decades. Prior to his